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Background: Ginsenoside Rb1 (G-Rb1), the major active constituent of ginseng, improves insulin sensi-
tivity and exerts antidiabetic effects. We tested whether the insulin-sensitizing and antidiabetic effects of
G-Rb1 results from a reduction in ectopic fat accumulation, mediated by inhibition of lipolysis in
adipocytes.
Methods: Obese and diabetic db/db mice were treated with daily doses of 20 mg/kg G-Rb1 for 14 days.
Hepatic fat accumulation was evaluated by measuring liver weight and triglyceride content. Levels of
blood glucose and serum insulin were used to evaluate insulin sensitivity in db/db mice. Lipolysis in
adipocytes was evaluated by measuring plasma-free fatty acids and glycerol release from 3T3-L1 adi-
pocytes treated with G-Rb1. The expression of relevant genes was analyzed by western blotting, quan-
titative real-time polymerase chain reaction, and enzyme-linked immunosorbent assay kit.
Results: G-Rb1 increased insulin sensitivity and alleviated hepatic fat accumulation in obese diabetic db/
db mice, and these effects were accompanied by reduced liver weight and hepatic triglyceride content.
Furthermore, G-Rb1 lowered the levels of free fatty acids in obese mice, which may contribute to a
decline in hepatic lipid accumulation. Corresponding to these results, G-Rb1 signiﬁcantly suppressed
lipolysis in 3T3-L1 adipocytes and upregulated the perilipin expression in both 3T3-L1 adipocytes and
mouse epididymal fat pads. Moreover, G-Rb1 increased the level of adiponectin and reduced that of
tumor necrosis factor-a in obese mice, and these effects were conﬁrmed in 3T3-L1 adipocytes.
Conclusion: G-Rb1 may improve insulin sensitivity in obese and diabetic db/db mice by reducing hepatic
fat accumulation and suppressing adipocyte lipolysis; these effects may be mediated via the upregulation
of perilipin expression in adipocytes.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier. All rights reserved.1. Introduction
Panax ginseng has been used for the treatment and prevention of
various diseases for several millennia in oriental medicine [1]. In
previous clinical and pharmacological studies, ginseng and its
active components have been reported to be effective in the
treatment of diabetes [2]. Ginsenosides are the major active con-
stituents responsible for the pharmacological properties of ginseng,
and G-Rb1 is the most abundant among > 40 ginsenosides [3,4].
Our previous studies showed that G-Rb1 stimulates glucose uptakeirst College of Clinical Medicine, N
g).
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ght  2015, The Korean Society ofthrough the insulin-like signaling pathway in 3T3-L1 adipocytes
[5], and facilitates adipogenesis of 3T3-L1 preadipocytes by
enhancing the expression of peroxisome proliferator-activated re-
ceptor g2 (PPARg2) and CCAAT/enhancer-binding protein a [6]. In
addition, we found that ginsenoside Rb1 can bind to PPARg as a
ligand and inhibited lipolysis in 3T3-L1 adipocytes [7]. Another
study reported that ginsenoside Rb1 has antiobesity and anti-
hyperglycemic effects in diet-induced obese rats [8]. Furthermore,
recent studies demonstrate that G-Rb1 can reduce liver fat accu-
mulation in high fat diet (HFD)-induced obese rats and mice [9,10].anjing University of Chinese Medicine, Nanjing 210023, China.
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J Ginseng Res 2015;39:199e205200In the pathogenesis of insulin resistance and diabetes, ectopic
fat deposition, which is deﬁned as the storage of triglycerides
within cells of nonadipose tissue, is postulated to play an important
role in the development of obesity-mediated insulin resistance [11].
In the obese and diabetic state, the level of circulating free fatty
acids (FFAs) is often elevated, and most FFAs have spilled over from
adipose tissue [11]. Circulating FFAs contribute to the incidence of
insulin resistance in two ways. One is that FFAs interfere with the
insulin-signaling pathway, and another is that they lead to exces-
sive accumulation of intracellular lipid products in the liver and
muscle [11,12]. Intrahepatic lipid content, and not visceral fat mass,
is primarily related to hepatic insulin resistance [13]. Several
interventional studies have demonstrated that a reduction in liver
fat in patients with type 2 diabetes mellitus (T2DM) can improve
insulin sensitivity and glucose metabolism [14,15]. Thus, reducing
the ectopic fat content represents an effective strategy for the
treatment of insulin resistance and T2DM.
Several factors contribute to lipid accumulation in the liver,
including increased FFA release from visceral fat depots, increased
lipogenesis, and reduced fatty acid oxidation in the liver. Failure to
suppress FFA release from adipose tissue is known to be more
important for fat accumulation in the liver [16]. Lipolysis in adi-
pocytes is regulated by a complex signaling cascade, among which
perilipin plays a central role in the regulation of lipolysis [17].
Perilipin double-regulates triacylglycerol (TG) metabolism by
blocking lipase from approaching droplets to reduce the rate of
basal lipolysis and facilitate hormonally stimulated lipolysis [18,19].
In 3T3-L1 adipocytes, the stimulation of lipolysis by tumor necrosis
factor-a (TNFa) is in part mediated by promoting the rapid degra-
dation of perilipin. Moreover, overexpression of perilipin in adi-
pocytes inhibited TNF-a induced lipolysis [20]. In perilipin-null
mice, basal adipocyte lipolysis was increased, and the development
of glucose intolerance and insulin resistance was also promoted,
probably due to the elevated levels of FFA [21].
Based on these observations, we hypothesized that G-Rb1 exerts
insulin-sensitizing and antidiabetic effects in part by inhibiting
lipolysis in adipocytes to reduce ectopic lipid accumulation in the
liver. To test this hypothesis, we investigated the effect of G-Rb1 on
hepatic lipid accumulation in obese diabetic db/db mice as well as
the effect of G-Rb1 on the expression of perilipin in adipocytes.
2. Materials and methods
2.1. Materials
G-Rb1, rosiglitazone, and dimethyl sulfoxide were obtained from
SigmaeAldrich (St Louis, MO, USA). Recombinant human insulinwas
purchased from Lily (Fegersheim, France) and recombinant mouse
TNFa from Gibco (Grand Island, NY, USA). Perilipin A goat polyclonal
antibody, adipose triglyceride lipase (ATGL) rabbit monoclonal anti-
body, and abhydrolase domain-containing 5 (ABHD5) goat poly-
clonal antibody from Abcam (Cambridge, MA, USA). Hormone
sensitive lipase (HSL) rabbit polyclonal antibody and phospho-HSL
(Ser563) rabbit polyclonal antibody were purchased from Cell
Signaling Technology (Beverly, MA, USA). b-actinmouse monoclonal
antibodywas purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The BCA protein assay kit andWest Pico chemiluminescent
substrate were purchased from Pierce (Rockford, IL, USA). Unless
otherwise speciﬁed, all other reagents were of analytic grade.
2.2. Animals and treatment
Male obese and diabetic db/db mice and their nondiabetic coun-
terparts,male C57BLKS/Jmice,were obtained fromMTE Ltd. (Jiangsu,
China). Mice were maintained on a 12/12 h light/dark cycle at 25C,and provided free access to standard rodent chow and tap water.
Diabeticdb/dbmicewere randomlydivided intotwogroups. In theG-
Rb1 treated group, G-Rb1 was administered by intraperitoneal in-
jection at a dose of 20 mg/kg body weight to nondiabetic mice, and
control animals received vehicle alone. Body weight and food intake
were recorded daily. After 14 d of treatment, themicewere fasted for
10 h, and blood was collected from the orbital vein of mice after they
were deeply anesthetized using sodium pentobarbital (30 mg/kg,
intraperitoneal). Epididymal fat and liver were surgically removed
andstoredat80Cuntil the assayswereperformed.All experiments
were approved by the Institutional Animal Care and Use Committee
of Nanjing University of Chinese Medicine, Nanjing, China.
2.3. Measurement of plasma samples
Plasma glucose levels were measured using a glucometer. In-
sulin was measured using a commercially available enzyme-linked
immunosorbent assay kit (Mercodia, Uppsala, Sweden). The ho-
meostasis model assessment of basal insulin resistance was used to
calculate an index from the product of the fasting concentrations of
plasma glucose (mM) and plasma insulin (mU/L) divided by 22.5
[22]. FFA content was measured using the LabAssay NEFA kit
(Wako, Osaka, Japan). Plasma concentrations of cholesterol, tri-
glycerides (TG), and high- and low-density lipoprotein cholesterol
were assessed with an autobiochemistry instrument using
biochemical methods. Serum TNFa and adiponectinweremeasured
using commercially available enzyme-linked immunosorbent assay
kits (Millipore, St Charles, MO, USA).
2.4. Liver TG assay
The liver TG assay was performed as previously described [23].
In brief, approximately 100 mg of liver tissue was digested over-
night with ethanolic KOH at 55C, and the digest was extracted
twice with 50% ethanol. After neutralization with MgCl2, the su-
pernatant was used for triglyceride measurement using a TG kit
(SigmaeAldrich).
2.5. Histological examination of the liver
Tissue sections were cut from frozen liver samples using a
microtome (Leica, Wetzlar, Germany) and mounted on gelatin-
coated slides. Oil red O staining was performed as previously
described [24]. In brief, the sections were ﬁxed in 4% formaldehyde
in phosphate-buffered saline for 1 h and then stained with 0.6% (w/
v) Oil Red O solution (60% isopropanol, 40% water) for 1 h at room
temperature. Sections were then washed three times with 60%
isopropanol to remove unbound dye and photographed at 100
magniﬁcation.
2.6. Measurement of lipolysis in 3T3-L1 adipocytes
Mouse 3T3-L1 ﬁbroblasts were obtained from the American Type
Culture Collection (Manassas, VA, USA). 3T3-L1 ﬁbroblasts were
cultured in Dulbecco’s modiﬁed Eagle’s medium supplementedwith
10% fetal bovine serum and differentiated into adipocytes as previ-
ously described [25]. On Day 10 of differentiation, 3T3-L1 adipocytes
were incubated with or without TNFa (10 ng/mL) in Dulbecco’s
modiﬁed Eagle’s medium containing 0.2% bovine serum albumin for
12 h. Subsequently, the medium was changed. Adipocytes were
treated with G-Rb1 or rosiglitazone at a concentration of 10mM in
the presence of 10 ng/mL TNFa for 24 h. After treatment, the me-
dium was removed and cells were incubated with phosphate-buff-
ered saline for 1 h. The glycerol content in the supernatant was
measured using free glycerol reagent (SigmaeAldrich).
Table 1
Effects of Rb1 on fasting metabolic parameters in obese diabetic db/db mice
Food intake (g/day) Body weight increment (g) Epididymal fat weight (%) FBG (mM) FSI (mg/L) HOMA-IR
BKS 16.79  1.59 1.24  0.66 1.32  0.30 6.38  2.28 0.93  0.98 0.24  0.13
db/db 24.71  1.21 4.38  1.04 6.16  0.91 17.42  2.74 9.29  3.03 7.15  1.29
G-Rb1 24.72  3.15 2.86  2.23 5.68  0.26 15.7  6.90 7.31  1.69* 4.42  1.61*
*p < 0.05 (db/db vs. G-Rb1 group).
FBG, fasting blood glucose; FSI, fasting serum insulin; HOMA-IR, homeostasis model assessment of insulin resistance.
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Total cellular proteins of liver samples and 3T3-L1 adipocytes
were extracted with homogenization buffer. Equal quantities of
protein (50 mg) were separated by 12% sodium dodecyl sulfatee
polyacrylamide gel electrophoresis and transferred onto poly-
vinylidene ﬂuoride membrane (Amersham International, Cardiff,
UK) using a Bio-Rad wet transfer unit. After blocking with 5% (w/v)
nonfat dried milk in Tris-buffered saline with Tween-20 solution
[25mM Tris, pH 7.5, 150mM NaCl, 0.05% (v/v) Tween-20] for 1 h at
room temperature, the membranes were incubated with a goat
anti-perilin A antibody (1:5000 dilution), rabbit anti-ATGL anti-
body (1:3000 dilution), rabbit anti-HSL antibody (1:1000 dilution),
rabbit anti-phospho-HSL (Ser563) antibody (1:1000 dilution), or
goat anti-ABHD5 antibody (1:3000) for 1 h at room temperature,
followed by horseradish peroxidase-conjugated second antibody
for 1 h at room temperature. Targeted proteins were detected with
ECL kit (Amersham Biosciences). b-actin was used to normalize the
amount of loaded protein.
2.8. Quantitative real-time polymerase chain reaction
Total RNA was extracted from 3T3-L1 cells with Trizol reagent
(Invitrogen, Carlsbad, CA, USA) and reverse-transcribed with Su-
perScript III Reverse Transcriptase and Oligo(dT) primer (Invi-
trogen). Quantitative real-time polymerase chain reaction was
performed using the Applied Biosystems 7500 Real-Time PCR
System (Applied Biosystems, Foster City, CA, USA). The following0
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Fig. 1. Ginsenoside-Rb1 signiﬁcantly reduced hepatic fat accumulation in obese and diabetic
with Oil Red O from pair-fed BKS mice (C), vehicle-treated db/db mice (D), and Rb1-treated
means  standard deviation (n ¼ 5), ## p < 0.05 vs. BKS, * p < 0.05 vs. db/db.primer sequences were used: TNFa, 50-ACG GCA TGG ATC TCA AAG
AC-30 (forward) and 50-CGG CAGAGAGGAGGT TGA CT-30 (reverse);
perilipin, 50-AAC CCT GCT GGA TGG AGA-30 (forward) and 50-TTT
GGT GCT GTT GTA GGT CTT-30 (reverse); and b-actin, 50-CGT TGA
CAT CCG TAA AGA CC-30 (forward) and 50-AAC GT CCG CCTAGA AGC
AC T-30 (reverse). Reaction speciﬁcity was controlled by post-
ampliﬁcation melting curve analyses and gel electrophoresis of
products. Quantitation of expression was achieved by normaliza-
tion to b-actin expression, and the results were analyzed using the
2DDCt relative quantitative method.
2.9. Statistical analysis
All values are expressed as mean  standard deviation values.
All in vitro data were obtained from at least three independent
experiments. Differences between two groups were determined
using Student t test. Differences among multiple groups were
determined by one-way analysis of variance followed by Fisher’s
least square difference post hoc test using the SPSS version 11.0
(SPSS Inc., Chicago, IL, USA). All p values < 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. G-Rb1 improves insulin sensitivity in db/db obese diabetic mice
In G-Rb1-treated db/db mice, fasting insulin levels and ho-
meostasis model assessment of basal insulin resistance were0
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db/db mice. (A) Mouse liver weight. (B) Mouse liver TG content. Liver sections stained
db/db mice (E), captured via light microscopy with a magniﬁcation of 100. Data are
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Fig. 2. Effects of ginsenoside-Rb1 on mice blood lipid proﬁles and FFA release from
adipocytes. (A) Plasma total cholesterol, triglycerides, and low-and high-density lipo-
protein cholesterol were tested using biochemical methods and expressed as mM.
Serum FFAs were measured use a nonesteriﬁed fatty acids (NEFA) test kit and
expressed as mEq/L serum. Data are means  standard deviation (n ¼ 5), # p < 0.05 vs.
BKS, ## p < 0.01 vs. BKS, * p < 0.05 vs. db/db, and ** p < 0.01 vs. db/db. (B) 3T3-L1
adipocytes were treated with TNFa only or with Rb1 simultaneously for 24 h, and then
cells were incubated with phosphate-buffered saline for 1 h. The glycerol content in
the supernatant was measured. Data are means  standard deviation (n ¼ 4), #
p < 0.01 vs. dimethyl sulfoxide, * p < 0.05 vs. TNFa, and ** p < 0.01 vs. TNFa. Rsg,
rosiglitazone; TNFa, tumor necrosis factor-a.
J Ginseng Res 2015;39:199e205202signiﬁcantly lower than those in vehicle-treated db/db mice after
14 days of treatment (Table 1, p < 0.05), whereas fasting glucose
levels showed a decreasing trend compared with those in vehicle-
treated db/db mice (p > 0.05). G-Rb1 treatment had no signiﬁcant
effect on the amount of food intake. Body weight gain and
epididymal fat weight were slightly reduced in G-Rb1-treated db/
db mice in comparison with these measurements for vehicle-
treated db/db mice (p> 0.05). These results suggest that the insulin
sensitising effect of G-Rb1 in db/db mice may not be dependent on
the inhibition of food uptake and reduction of adiposity.
3.2. G-Rb1 reduces liver fat accumulation in db/db obese diabetic
mice
In the present study, we investigated whether G-Rb1 exerts
insulin-sensitizing and antidiabetic effects in part by reducing
ectopic TG accumulation in the body. The weight of the liver and
hepatic TG content were signiﬁcantly lower in the G-Rb1-treated
db/db mice than in the vehicle-treated controls (Fig. 1A, B). Oil Red
O staining, which indicates lipid droplet accumulation in the
cytoplasm, revealed numerous large lipid droplets in vehicle-
treated db/db mice, whereas only scattered and smaller lipid
droplets in G-Rb1-treated db/db mice, and no droplets in pair-fed
normal BKS mice (Fig. 1CeE).
3.3. G-Rb1 decreases circulating FFA levels in diabetic mice and
lipolysis in adipocytes
To determine the potential mechanisms by which G-Rb1 re-
duces hepatic fat accumulation in obese and diabetic db/db mice,
circulating levels of FFAs and total cholesterol, TG, and high- and
low-density lipoprotein cholesterol were tested. As shown in
Fig. 2A, plasma FFA levels were signiﬁcantly lower in G-Rb1-treated
db/db mice than in vehicle-treated mice (p < 0.05; Fig. 2A). In
addition, the plasma TG level appeared to be lower in G-Rb1-
treated db/db mice than in vehicle-treated mice; however, this
difference was not signiﬁcant. Because low levels of circulating FFA
could result from decreased lipolysis in adipocytes, we further
investigated the effect of G-Rb1 on lipolysis in 3T3-L1 adipocytes.
Glycerol released from TNFa-stimulated adipocytes clearly
increased. The glycerol concentration in the supernatant was
reduced by approximately 9% in G-Rb1-treated 3T3-L1 adipocytes
(p < 0.05; Fig. 2B). These results suggest that G-Rb1 could lower
circulating FFA levels by inhibiting lipolysis.
3.4. G-Rb1 upregulates perilipin expression in adipocytes
To elucidate the mechanism responsible for the effects of G-Rb1,
several proteins that directly participate in lipolysis were
measured. As shown in Fig. 3B, after pretreatment with TNFa, the
expression of HSL, ABHD5, and perilipin Awas signiﬁcantly reduced
(Fig. 3A, B, p < 0.01), and the expression of ATGL and HSL phos-
phorylation showed no signiﬁcant change. The expression of per-
ilipin A recovered when TNFa-pretreated 3T3-L1 adipocytes were
incubated with G-Rb1 for 24 h. These observations were further
conﬁrmed in the epididymal fat pads of G-Rb1 or treated mice
(Fig. 3C). The results suggest that the inhibiting effect of G-Rb1 on
lipolysis adipocytes may result from the recovered expression of
downregulated perilipin A.
3.5. G-Rb1 decreases TNFa and increases adiponectin in db/db mice
and adipocytes
Compared with pair-fed normal BKS mice, db/db mice have
lower levels of adiponectin and higher levels of TNFa. After 14-daysof treatment with G-Rb1, TNFa decreased and adiponectin signiﬁ-
cantly increased in G-Rb1-treated mice compared with those in
vehicle-treated db/db mice (Fig. 4A, B, p < 0.05). In 3T3-L1 adipo-
cytes, G-Rb1 upregulated the mRNA expression of adiponectin and
partially recovered the suppressed expression of adiponectin
induced by TNFa (Fig. 4C, p < 0.05). By contrast, G-Rb1 reduced the
overexpression of TNFa stimulated by pretreatment with TNFa
(Fig. 4D, p < 0.05).
4. Discussion
In the past decade, numerous in vitro and in vivo studies have
demonstrated that ginseng and ginsenosides exert signiﬁcant
antidiabetic effects, such as lowering blood glucose, increasing in-
sulin sensitivity, and regulating lipid metabolism and inﬂammatory
pathways in both insulin-dependent and -independent manners
[2]. G-Rb1, the most abundant and most important active compo-
nent in ginseng, has been reported to exert antiobesity and anti-
hyperglycemic effects in HFD-induced obese rats [8]. Our previous
studies showed that G-Rb1 can promote glucose uptake and inhibit
lipolysis in 3T3-L1 adipocytes [5e7]. In the present study, we found
that G-Rb1 treatment improved insulin sensitivity and reduced
liver fat content in obese diabetic db/db mice. Meanwhile, G-Rb1
treatment upregulated the expression of perilipin in adipose tissue
and reduced the circulating FFA concentration. Because ectopic fat
accumulation induced by overload of FFA is an important cause of
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Fig. 3. Ginsenoside-Rb1 increased perilipin A expression in adipocytes. (A) and (B) Proteins were isolated from the 3T3-L1 cell lysates and analyzed by western blot analysis. The
experiments were repeated three times. Data are means  standard deviation (n ¼ 3), # p < 0.01 vs. dimethyl sulfoxide, * p < 0.01 vs. TNFa, and ** p < 0.01 vs. TNFa (C) and (D)
proteins were isolated from the epididymal fat pad lysates and analyzed by western blot analysis. The experiments were repeated three times. Data are means  standard deviation
(n ¼ 3), ## p < 0.01 vs. BKS, and * p < 0.05 vs. db/db. b-actin was used for normalization of the amount of loaded protein. TNFa, tumor necrosis factor-a.
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Fig. 4. The effects of ginsenoside-Rb1 on the mRNA and concentration of adiponection and tumor necrosis factor-a (TNFa). (A) and (B) serum adiponectin and TNFa were analyzed
by commercially available enzyme-linked immunosorbent assay kits. Data are means  standard deviation (n ¼ 5), ## p < 0.05 vs. BKS, * p < 0.05 vs. db/db (C) and (D) 3T3-L1
adipocytes were treated with TNF-a only or with Rb1 simultaneously for 24 h. Total RNA was extracted from 3T3-L1 cells and analyzed by quantitative real-time polymerase chain
reaction for adiponectin and TNFa. Data are means  standard deviation (n ¼ 3), # p < 0.01 vs. control, and *p < 0.01 vs. TNFa.
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J Ginseng Res 2015;39:199e205204insulin resistance [11,16], these results imply that G-Rb1 can
upregulate the expression of perilipin in adipose tissue to amelio-
rate liver fat accumulation, which offers an improved under-
standing of the mechanisms of the insulin-sensitizing and
antidiabetic effects of G-Rb1.
Fat accumulation within the liver occurs as a consequence of
continuous oversupply of FFA together with reduced FFA oxidation
in the mitochondria [26]. Shen et al [9] recently reported that, after
chronic intraperitoneal administration, G-Rb1 signiﬁcantly
ameliorated hepatic fat accumulation in HFD-induced obese rats,
and this effect was associated with elevated activation of hepatic
AMP-activated protein kinase, which ultimately stimulated fatty
acid oxidative gene expression and suppressed the expression of
genes encoding enzymes or proteins that function in lipogenesis.
Enhanced FFA release from adipose tissue in obesity is more
important in the progress of fat accumulation in the liver [16]. In
the present study, we found that G-Rb1 upregulated the expression
of perilipin to inhibit FFA release from adipocytes and in obese
diabetic db/db mice, which implies another mechanism by which
G-Rb1 regulates hepatic fat accumulation.
Adipose tissue is an important site of FFA liberation into the
plasma. In the fasting state, plasma FFA is derived almost exclu-
sively from hydrolysis of TG within adipocytes [27]. The increase
plasma FFAs observed in obese patients is believed to result from
dysregulated lipolysis of TG in adipose cells [27]. Thus, we postu-
lated that the decreased plasma FFA concentrations in obese and
diabetic db/db mice treated with G-Rb1 may be caused by
enhanced inhibition of intracellular lipolysis in adipose tissue. We
found that G-Rb1 signiﬁcantly prevented lipolysis in 3T3-L1 cells
pretreated with TNFa in this study. Although lipolysis in adipocytes
is highly regulated through modulation of the activity of multiple
enzymes and conformation of the proteins that coat the adipocyte
lipid droplet, perilipin has been shown to play a key role of in
lipolytic activation of adipocytes [18]. Perilipin is the most abun-
dant protein on the surface of lipid droplets, and also the major
substrate of protein kinase A in hormonally stimulated lipolysis.
Under basal conditions, HSL is located in the cytoplasm, while
nonphosphorylated perilipin coats the lipid droplets and binds to
ABHD5, which is a key activator of ATGL [18,19]. This restricts the
actions of lipases on stored neutral lipids and promotes TG storage.
During energy deﬁcit, protein kinase A is activated by cAMP, which
phosphorylates both perilipin and HSL. This induces a conforma-
tional change of perilipin, which facilitates the HSL docking, by
which phosphorylated HSL gains access to substrates at the surface
of lipid droplets. In addition, phosphorylated perilipin releases
ABHD5, which then binds to ATGL and activates this enzyme
[19,28]. Taysey et al [21] reported that perilipin ablation results in
lean mice with reduced adipose tissue mass, high levels of basal
lipolysis, and peripheral insulin resistance. The expression of per-
ilipin A is reduced in poorly controlled patients with T2DM [29]. In
our study, perilipin expression in the adipose tissue of db/db obese
mice was lower than that in normal lean mice, and circulating FFA
levels were elevated in obese mice. G-Rb1 partly recovered the
downregulated expression of perilipin in obese mice, and reduced
the level of circulated FFA, without affecting the expression of ATGL
or HSL, which was conﬁrmed in 3T3-L1 adipocytes treated with
TNFa. These results indicate that the increase in perilipin induced
by G-Rb1 may represent the underlying mechanism for the inhi-
bition of lipolysis and reduction in plasma FFA concentrations.
The precise mechanism underlying the regulation of perilipin by
G-Rb1 has not been identiﬁed in this study. It has been demon-
strated that the expression of perilipin is regulated by PPARg in
adipocytes [30,31]. The insulin-sensitizing effect of multiple PPAR
agonists is mediated via increased expression of perilipin to reduce
plasma FFA concentrations and ectopic fat accumulation [32,33]. Inour previous study, we found that G-Rb1 can not only promote the
expression of PPARg2 but also directly bind to PPARg2 as a ligand to
increase its activity [6,7]. Although we did not detect PPARg
expression, the upregulating effect of G-Rb1 on perilipin probably
results from its activation of PPARg in adipocytes. By contrast, TNFa
production is increased in obese patients with T2DM and may lead
to enhanced basal lipolysis in obesity through the downregulation
of perilipin mRNA and protein expression in adipose tissue [34,35].
Our results showed that G-Rb1 could reduce TNFa concentration in
obese mice and suppress the expression of TNFa in adipocytes,
which may contribute to the effect of G-Rb1 on perilipin and
lipolysis. In addition, we found that G-Rb1 upregulated the
expression of adiponectin in adipocytes and increased the level of
adiponectin in obese mice. There has been no report on the rela-
tionship between adiponectin and perilipin, but adiponectin, as an
adipocytokine, that improves insulin sensitivity induced by obesity
[36], also inhibits lipolysis in adipocytes [37]. Thus, the elevated
adiponectin expression induced by G-Rb1 may be helpful for
inhibiting the effects of G-Rb1 on lipolysis and insulin resistance.
In conclusion, this study revealed that G-Rb1, the most abun-
dant ginsenoside in ginseng root, improves insulin sensitivity in
obese and diabetic db/db mice by reducing hepatic fat accumula-
tion and suppressing adipocyte lipolysis, which may be mediated
by the upregulation of perilipin expression in adipocytes. The
ﬁndings promote an improved understanding of the mechanism of
the insulin-sensitizing and antidiabetic effects of G-Rb1.
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